← All trials
NCT05187481
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Jul 31, 2024
- Completion date
- Jul 31, 2024
- First posted
- Jan 11, 2022
- Last posted
- Jan 11, 2022
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesCollaborator
- China Academy of Chinese Medical SciencesCollaborator
- China Academy of Chinese Medical SciencesStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.